Security
Editas Medicine, Inc. Common Stock · EDIT
EDITNASDAQCommon stockCurrentCIK 1650664Updated Oct 9, 2026
EDIT price & chart
Loading TradingView…
NASDAQ:EDIT on TradingView ↗About the company
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.
In the news
Editas Medicine Announces Proposed Public Offering ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
S-8 filing
EFFECT filing
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 186,534,000Source | 341,589,000Source | 499,153,000Source | 514,321,000Source |
| Property, Plant and Equipment, NetUSD | 3,542,000Source | 14,497,000Source | 12,032,000Source | 15,569,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 146,645,000Source | 131,541,000Source | 123,652,000Source | 141,522,000Source |
| Assets, CurrentUSD | 163,895,000Source | 289,315,000Source | 340,829,000Source | 356,754,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,074,000Source | 3,136,000Source | 7,531,000Source | 7,335,000Source |
| Operating Lease, Right-of-Use AssetUSD | 16,121,000Source | 32,554,000Source | 33,680,000Source | 43,648,000Source |
| Other Assets, NoncurrentUSD | 2,976,000Source | 5,223,000Source | 8,588,000Source | 5,253,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 159,246,000Source | 207,315,000Source | 150,056,000Source | 153,641,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 10,000Source | 8,000Source | 8,000Source | 7,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,628,503,000Source | -1,468,443,000Source | -1,231,350,000Source | -1,078,131,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 268,000Source | 198,000Source | -3,601,000Source |
| Stockholders' Equity Attributable to ParentUSD | 27,288,000Source | 134,274,000Source | 349,097,000Source | 360,680,000Source |
| Additional Paid in Capital, Common StockUSD | 1,655,781,000Source | 1,602,441,000Source | 1,580,241,000Source | 1,442,405,000Source |
| Liabilities and EquityUSD | 186,534,000Source | 341,589,000Source | 499,153,000Source | 514,321,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 46,246,000Source | 77,225,000Source | 63,217,000Source | 60,110,000Source |
| Operating Lease, Liability, CurrentUSD | 6,031,000Source | 14,652,000Source | 12,164,000Source | 11,082,000Source |
| Accounts Payable, CurrentUSD | 2,605,000Source | 5,493,000Source | 8,269,000Source | 9,511,000Source |
| Operating Lease, Liability, NoncurrentUSD | 12,071,000Source | 20,380,000Source | 24,372,000Source | 32,864,000Source |
| Other Liabilities, NoncurrentUSD | 2,815,000Source | 3,072,000Source | 1,800,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 32,610,000Source | 45,859,000Source | 34,563,000Source | 31,296,000Source |
| Long-term Debt, Current MaturitiesUSD | 5,000,000Source | 5,000,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 53,605,000Source | 52,434,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -220,432,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,000,000Source | 21,417,000Source | 19,798,000Source | 29,294,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -1,090,000Source | 6,079,000Source | 5,042,000Source | 4,878,000Source |
| Increase (Decrease) in Accounts PayableUSD | -2,888,000Source | -2,286,000Source | -1,492,000Source | 4,368,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -165,241,000Source | -210,284,000Source | -132,178,000Source | -177,349,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 138,668,000Source | 162,146,000Source | -3,731,000Source | 114,068,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 607,000Source | 8,826,000Source | 4,719,000Source | 4,118,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 40,470,000Source | 56,027,000Source | 118,039,000Source | 1,284,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 13,897,000Source | 7,889,000Source | -17,870,000Source | -61,997,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 149,315,000Source | 135,418,000Source | 127,529,000Source | 145,399,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,000,000Source | 21,417,000Source | 19,798,000Source | 29,294,000Source |
| Amortization of Debt Issuance CostsUSD | — | 62,000Source | — | — |
| DepreciationUSD | 5,277,000Source | 5,809,000Source | 6,064,000Source | 6,337,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -2,193,000Source | -149,000Source | — | — |
| General and Administrative ExpenseUSD | 49,903,000Source | 71,987,000Source | 69,653,000Source | 70,704,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 2,128,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -160,060,000Source | -237,093,000Source | -153,219,000Source | -220,432,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -220,432,000Source |
| Nonoperating Income (Expense)USD | -50,000Source | 14,059,000Source | 15,962,000Source | 5,518,000Source |
| Operating ExpensesUSD | 200,530,000Source | 283,466,000Source | 247,304,000Source | 245,662,000Source |
| Other Nonoperating Income (Expense)USD | -2,189,000Source | -3,000Source | -1,604,000Source | 1,293,000Source |
| Proceeds from Issuance of Common StockUSD | 42,848,000Source | 0Source | 117,079,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 70,000Source | 193,000Source | 41,000Source | 305,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 40,520,000Source | 32,314,000Source | 78,123,000Source | 19,712,000Source |
| Operating Income (Loss)USD | -160,010,000Source | -251,152,000Source | -169,181,000Source | -225,950,000Source |
| Other Nonoperating Income (Expense)USD | -2,189,000Source | -3,000Source | -1,604,000Source | 1,293,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -160,060,000Source | -237,093,000Source | -153,219,000Source | -220,432,000Source |
| Earnings Per Share, BasicUSD per share | -1.8Source | -2.88Source | -2.02Source | -3.21Source |
| Earnings Per Share, DilutedUSD per share | -1.8Source | -2.88Source | -2.02Source | -3.21Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 88,745,908Source | 82,338,220Source | 75,965,633Source | 68,664,822Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 88,745,908Source | 82,338,220Source | 75,965,633Source | 68,664,822Source |
| Interest Expense (non-operating)USD | 2,128,000Source | — | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 49,903,000Source | 71,987,000Source | 69,653,000Source | 70,704,000Source |
| Interest Expense, DebtUSD | 6,171,000Source | 2,128,000Source | — | — |
| Investment Income, NetUSD | 8,310,000Source | 14,062,000Source | 17,566,000Source | 4,225,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -220,432,000Source |
| Nonoperating Income (Expense)USD | -50,000Source | 14,059,000Source | 15,962,000Source | 5,518,000Source |
| Operating ExpensesUSD | 200,530,000Source | 283,466,000Source | 247,304,000Source | 245,662,000Source |
| Research and Development ExpenseUSD | 89,953,000Source | 199,247,000Source | 177,651,000Source | 174,958,000Source |
Offerings
Registration 333-298665
Registration 333-296213
Filing attachments
tm2624301d2_ex4-4.htm · S-3 · 2026-08-31
Exhibit 4.4 Editas Medicine, Inc. and _______________ Trustee INDENTURE Dated as of _______________ SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Section of Trust Indenture Act Indenture of 1939, as amended ───────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13…
Read attachment ↗tm2624301d2_ex4-5.htm · S-3 · 2026-08-31
Exhibit 4.5 Editas Medicine, Inc. and Trustee INDENTURE Dated as of _______________ SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act Section of of 1939, as amended Indenture ──────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) …
Read attachment ↗tm2624301d2_ex4-6.htm · S-3 · 2026-08-31
Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF S…
Read attachment ↗tm2624301d2_ex4-7.htm · S-3 · 2026-08-31
Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINE…
Read attachment ↗tm2615565d3_ex4-1.htm · 8-K · 2026-05-26
EX-4.1 3 tm2615565d3_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 FORM OF WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Number of Shares: [· ] (subject to adjustment) Warrant No. [·] Original Issue Date: May [·], 2026 ─────────────────────────────────────────────────────────── Editas Medicine, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [· ] or its registere…
Read attachment ↗tm2615565d3_ex99-1.htm · 8-K · 2026-05-26
EX-99.1 5 tm2615565d3_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering CAMBRIDGE, Mass., May 26, 2026 - Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common…
Read attachment ↗